Valuation: Unicycive Therapeutics, Inc.

Market Cap 152M 130M 122M 111M 209M 14.53B 212M 1.44B 561M 7.3B 570M 558M 24.13B P/E 2026 *
-4.51x
P/E 2027 * 3.38x
Enterprise Value 152M 130M 122M 111M 209M 14.53B 212M 1.44B 561M 7.3B 570M 558M 24.13B EV / Sales 2026 *
551x
EV / Sales 2027 * 1.04x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * 38.2%
1 day+3.30%
1 week+2.18%
Current month+12.38%
1 month-1.05%
3 months-26.21%
6 months-14.31%
Current year-2.43%
1 week 5.4
Extreme 5.405
5.85
1 month 4.71
Extreme 4.71
5.85
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31.9
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap.
14/5/26 Free

Chief Executive Officer

762,200 3.0201%
25/8/25
Vivo Capital LLC
ConversionCompany 652,900 5.1135%
28/7/25 Free

Chief Executive Officer

325,000 2.5454%
Change 5-day change 1-year change 3-year change Capi.($)
+3.30%+2.18%+32.47%-31.27% 152M
-3.00%+0.33%+77.39%+109.41% 73.96B
+1.90%+19.57%+60.16%+101.03% 64.66B
+0.55%+1.64%-5.15%+471.68% 27.32B
+5.12%+25.22%+5.24%-0.82% 27.86B
+2.74%+11.55%+66.56%+27.34% 25.97B
+0.47%+6.22%+39.36%-12.38% 19.98B
+1.82%-3.11%+245.72%+423.83% 17.84B
+0.94%+2.38%+24.83%+552.12% 16.24B
+0.73%+5.54%+39.71%+153.07% 13.3B
Average +1.37%+5.64%+58.63%+179.40% 28.73B
Weighted average by Cap. +0.60%+6.66%+60.75%+161.90%

Financials

2026 *2027 *
Net sales 275K 236K 221K 202K 379K 26.35M 384K 2.61M 1.02M 13.24M 1.03M 1.01M 43.78M 145M 125M 117M 107M 200M 13.91B 203M 1.38B 537M 6.99B 546M 534M 23.12B
Net income -34.12M -29.23M -27.35M -25.03M -46.98M -3.26B -47.6M -323M -126M -1.64B -128M -125M -5.42B 46.27M 39.63M 37.08M 33.94M 63.7M 4.43B 64.55M 438M 171M 2.22B 174M 170M 7.36B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
22/08/26 US$5.630 +3.30% 1,013,087
20/08/26 US$5.450 -2.33% 643,258
19/08/26 US$5.580 -0.89% 845,888
18/08/26 US$5.630 +1.08% 738,895
17/08/26 US$5.570 +1.09% 576,076
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.450USD
Average target price
28.22USD
Spread / Average Target
+417.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock